Vapreotid

Vapreotid
Klinički podaci
Prodajno imeSanvar, Sanvar IR
Drugs.comMonografija
Farmakokinetički podaci
Poluvreme eliminacije30 minuta
Identifikatori
CAS broj103222-11-3 ДаY
ATC kodH01CB04 (WHO)
PubChemCID 23725064
DrugBankDB04894 ДаY
ChemSpider64425 ДаY
Hemijski podaci
FormulaC57H70N12O9S2
Molarna masa1131,371
  • CC(C)C1NC(=O)C(CCCCN)NC(=O)C(CC2=CNC3=C2C=CC=C3)NC(=O)C(CC2=CC=C(O)C=C2)NC(=O)C(CSSCC(NC1=O)C(=O)NC(CC1=CC2=CC=CC=C2N1)C(N)=O)NC(=O)C(N)CC1=CC=CC=C1
  • InChI=1S/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)28-37-26-35-14-6-8-16-41(35)62-37)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-38(70)22-20-34)53(74)66-46(27-36-29-61-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,26,29,32,40,43-49,61-62,70H,10-11,18,23-25,27-28,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73) ДаY
  • Key:GAWXLRUZZFSQON-UHFFFAOYSA-N ДаY

Vapreotid je organsko jedinjenje, koje sadrži 57 atoma ugljenika i ima molekulsku masu od 1131,371 Da.[1][2][3][4][5][6][7][8][9]

Osobine

[уреди | уреди извор]
Osobina Vrednost
Broj akceptora vodonika 13
Broj donora vodonika 13
Broj rotacionih veza 18
Particioni koeficijent[10] (ALogP) 3,2
Rastvorljivost[11] (logS, log(mol/L)) -13,3
Polarna površina[12] (PSA, Å2) 401,2

Reference

[уреди | уреди извор]
  1. ^ Sarr, M. G.; Pancreatic Surgery Group (2003). „The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: A prospective, multicenter, double-blinded, randomized, placebo-controlled trial”. Journal of the American College of Surgeons. 196 (4): 556—64; discussion 564—5; author reply 565. PMID 12691930. doi:10.1016/S1072-7515(03)00104-2. 
  2. ^ „Vapreotide: BMY 41606, RC 160, Sanvar”. Drugs in R&D. 4 (5): 326—30. 2003. PMID 12952505. S2CID 241912168. doi:10.2165/00126839-200304050-00010. 
  3. ^ Norman, P. (новембар 2000). „Vapreotide (Debipharm)”. Idrugs : The Investigational Drugs Journal. 3 (11): 1358—72. PMID 16047258. 
  4. ^ Betoin, F.; Ardid, D.; Herbet, A.; Aumaitre, O.; Kemeny, J. L.; Duchene-Marullaz, P.; Lavarenne, J.; Eschalier, A. (април 1994). „Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism”. The Journal of Pharmacology and Experimental Therapeutics. 269 (1): 7—14. PMID 7909563. 
  5. ^ Girard, P. M.; Goldschmidt, E.; Vittecoq, D.; Massip, P.; Gastiaburu, J.; Meyohas, M. C.; Coulaud, J. P.; Schally, A. V. (јул 1992). „Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases”. Aids (London, England). 6 (7): 715—8. PMID 1354449. S2CID 21204910. doi:10.1097/00002030-199207000-00015. }-
  6. ^ Stiefel, F.; Morant, R. (јануар 1993). „Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer”. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 1 (1): 57—8. PMID 7511473. S2CID 5672220. doi:10.1007/BF00326640. }-
  7. ^ Betoin, F.; Eschalier, A.; Duchene-Marullaz, P.; Lavarenne, J. (1994-01-31). „Seven-day antinociceptive effect of a sustained release vapreotide formulation”. NeuroReport. 5 (5): 642—4. PMID 7912964. doi:10.1097/00001756-199401000-00028. }-
  8. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  9. ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  10. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  11. ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  12. ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

[уреди | уреди извор]

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).